Deliver Your News to the World

Ossianix Announces Strategic Research Collaboration with Lundb


PHILADELPHIA, PA: Ossianix, Inc. announced a strategic research collaboration with Lundbeck A/S. This collaboration follows a previous investment in 2012. The collaboration uses Ossianix’s innovative single domain antibody platform based on the shark VNAR structure and will focus on two projects. The first project will further develop Ossianix’s VNAR antagonists targeting an ion channel for the treatment of pain. The second project utilizes Ossianix’s Blood Brain Barrier targeting technology for the development of bispecific biopharmaceuticals to treat CNS disorders. The Ossianix platform has the advantage of targeting antibodies to the CNS where existing
antibodies have proven less than ideal due to poor bioavailability. Lundbeck will fund the research plan with development and regulatory milestones. Dr. Frank Walsh, Ossianix CEO, stated: “We are pleased to continue and extend our strategic relationship with Lundbeck. The VNAR platform has shown its potential in isolating potent and specific biopharmaceuticals to difficult drug targets and in developing strategies for CNS drug delivery. We will now proceed in partnership with Lundbeck with the goal of moving products to the clinic. ”Dr. Kim Andersen, Vice President of Research for Lundbeck, said: “We at Lundbeck have been impressed by the progress Ossianix has made following our initial investment and we look forward to a further productive relationship. This will allow us to develop novel biopharmaceuticals for very difficult CNS drug targets"

About Ossianix
Ossianix is a privately held research company based in Philadelphia, PA with research laboratories in the UK. It develops novel biopharmaceuticals for a number of therapeutic areas including CNS. The company utilizes the versatile single domain shark VNAR scaffold to engineer unique differentiated products in a variety of formats including monospecific and bispecifics. The company was founded by two former senior executives from Wyeth and Pfizer, Drs. Frank S. Walsh and Corey S. Goodman. Ossianix is currently funded by Lundbeck, Bio Advance and other angel investors as well as non dilutive grants. For more information please visit


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.